Prize Competition for Maternal Health
NIBIB launched the NIH Technology Accelerator Challenge (NTAC) series of prize competitions to stimulate the design of new diagnostic technologies to transform public and global health and to accelerate the full development of those products for use in low-resource settings. This iteration of NTAC awarded cash prizes for innovative diagnostic technologies to help improve maternal health by diagnosing conditions related to maternal morbidity and mortality. Pregnancy and childbirth complications are a major global health problem resulting in the deaths of more than 800 women and 7,000 newborns each day. Contributing to the high rates of maternal morbidity and mortality in low-resource settings is the lack of low-cost diagnostics that operate at the point-of-care and are capable of detecting and differentiating common conditions during antenatal and intrapartum periods of pregnancy. Therefore, the intended purpose of NTAC: Maternal Health was to spur and reward the development of low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies integrated with a digital platform to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality.
See links below to the 2022 prize winners and winner showcase webinar.
NTAC for Maternal Health Winner Showcase Webinar
Challenge winners presented their technologies at the VentureWell-hosted NTAC for Maternal Health Winner Showcase webinar.
NTAC for Maternal Health Announcement
Related News
NIH today announced the winners of its NIH Technology Accelerator Challenge (NTAC) for Maternal Health, a prize competition for developers of diagnostic technologies to help improve maternal health around the world.
Awards will support innovative technologies to help improve maternal health around the world.
The National Institutes of Health has launched a $1 million Technology Accelerator Challenge (TAC) to spur the design and development of non-invasive, handheld, digital technologies to detect, diagnose, and guide therapies for diseases with high global and public health impact.